Skip to main content

Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.

Publication ,  Journal Article
Hatch, AJ; Clarke, JM; Nixon, AB; Hurwitz, HI
Published in: Cancer J
2015

Agents that inhibit tumor angiogenesis are widely used and have provided meaningful survival benefits to patients in multiple disease settings. However, these agents differ significantly in their mechanisms of action and potential toxicities, and there are currently no prospectively validated biomarkers to guide the selection of agents for individual patients. Blood-based protein biomarkers are well suited for trials investigating antiangiogenic agents for multiple reasons. Many elements of the molecular pathways that antiangiogenic agents target are present and detectable in the circulation, sample collection is minimally invasive, and samples can be collected throughout the course of treatment. Blood-based biomarkers for antiangiogenic therapies are urgently needed to guide the development of therapeutic strategies. This review provides a brief summary of the current blood-based protein biomarkers for antiangiogenic therapies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer J

DOI

EISSN

1540-336X

Publication Date

2015

Volume

21

Issue

4

Start / End Page

322 / 326

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factors
  • Treatment Outcome
  • Recombinant Fusion Proteins
  • Receptors, Vascular Endothelial Growth Factor
  • Ramucirumab
  • Protein-Tyrosine Kinases
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neovascularization, Pathologic
  • Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hatch, A. J., Clarke, J. M., Nixon, A. B., & Hurwitz, H. I. (2015). Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress. Cancer J, 21(4), 322–326. https://doi.org/10.1097/PPO.0000000000000129
Hatch, Ace J., Jeffrey M. Clarke, Andrew B. Nixon, and Herbert I. Hurwitz. “Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.Cancer J 21, no. 4 (2015): 322–26. https://doi.org/10.1097/PPO.0000000000000129.
Hatch AJ, Clarke JM, Nixon AB, Hurwitz HI. Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress. Cancer J. 2015;21(4):322–6.
Hatch, Ace J., et al. “Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.Cancer J, vol. 21, no. 4, 2015, pp. 322–26. Pubmed, doi:10.1097/PPO.0000000000000129.
Hatch AJ, Clarke JM, Nixon AB, Hurwitz HI. Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress. Cancer J. 2015;21(4):322–326.

Published In

Cancer J

DOI

EISSN

1540-336X

Publication Date

2015

Volume

21

Issue

4

Start / End Page

322 / 326

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factors
  • Treatment Outcome
  • Recombinant Fusion Proteins
  • Receptors, Vascular Endothelial Growth Factor
  • Ramucirumab
  • Protein-Tyrosine Kinases
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neovascularization, Pathologic
  • Neoplasms